InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Newman James W. Jr., Director. Director active across 1 companies, notably Adial Pharmaceuticals, INC.. Cumulatively, 4 disclosures have been published. Total volume traded: €98k. The latest transaction was disclosed on 30 December 2021 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations4 total
€23,41510,000 shares@ €2.341547.9% of flow
Common Stock
SEC:0001213900-22-000067·
Ideal exit: 26 Sept 2022 (T+270)
€23,41510,000 shares@ €2.34150.79% mcap24.0% of flow
Common Stock
SEC:0001213900-22-000067:0·
Ideal exit: 26 Sept 2022 (T+270)
€25,42510,000 shares@ €2.542552.1% of flow
Common Stock
SEC:0001213900-21-062465·
Ideal exit: 23 Aug 2022 (T+270)
€25,42510,000 shares@ €2.54250.86% mcap26.0% of flow
Common Stock
SEC:0001213900-21-062465:0·
Ideal exit: 23 Aug 2022 (T+270)
4 of 4 declarations
About Newman James W. Jr.
James W. Newman Jr. is a Director at ADIAL PHARMACEUTICALS, INC. He oversees the company's activities and participates in strategic decision-making. His expertise in the pharmaceutical field allows him to make significant contributions to the company's governance.
